Statement Of Cash Flows [Abstract]
| Concept |
2020-01-01 to 2020-12-31 |
2019-01-01 to 2019-12-31 |
|---|---|---|
| Statement of cash flows [abstract] | ||
| Cash flows from (used in) operating activities [abstract] | ||
| Adjustments for finance income (cost) |
150,000,000
EUR
|
168,000,000
EUR
|
| Increase (decrease) in working capital |
195,000,000
EUR
|
240,000,000
EUR
|
| Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss |
609,000,000
EUR
|
597,000,000
EUR
|
| Adjustments for gains (losses) on change in fair value less costs to sell, biological assets |
428,000,000
EUR
|
442,000,000
EUR
|
| Adjustments for undistributed profits of investments accounted for using equity method |
1,000,000
EUR
|
229,000,000
EUR
|
| Cash flows from (used in) investing activities [abstract] | ||
| Purchase of interests in investments accounted for using equity method |
2,000,000
EUR
|
7,000,000
EUR
|
| Purchase of biological assets |
79,000,000
EUR
|
88,000,000
EUR
|
| Purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets |
582,000,000
EUR
|
510,000,000
EUR
|
| Proceeds from disposals of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets |
17,000,000
EUR
|
12,000,000
EUR
|
| Cash flows from (used in) financing activities [abstract] | ||
| Proceeds from non-current borrowings |
1 081
EUR
|
870,000,000
EUR
|
| Proceeds from contributions of non-controlling interests |
0
EUR
|
4,000,000
EUR
|